75 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
leading cause of cancer-related death in the United States among both men and women. Based on the National Cancer Institute, Surveillance, Epidemiology
8-K
EX-99.1
CADL
Candel Therapeutics Inc
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic cancer is a highly lethal malignancy, and is the fourth leading cause of cancer-related death
8-K
EX-99.1
CADL
Candel Therapeutics Inc
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
is a highly lethal malignancy, and is the fourth leading cause of cancer-related death in the United States among both men and women. Based on the National
8-K
EX-99.1
knike60dbo9x42lr4fq
9 Nov 23
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
8:16am
8-K
EX-99.1
3fzp11 bor66tqi
6 Nov 23
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
8:53am
8-K
EX-99.1
2rgb87wvq4lc4df8
6 Nov 23
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:15am
8-K
EX-99.1
alewut
18 Oct 23
Regulation FD Disclosure
11:31am
8-K
EX-99.1
xerln6th5htezal
26 Sep 23
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
8:30am
8-K
EX-99.1
cu5ogd8laz2zkcq
10 Aug 23
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8:15am
8-K
5ghpf0 9t7ug
29 Jun 23
Submission of Matters to a Vote of Security Holders
8:31am
8-K
EX-99.1
kyubhw50lqg1k qn90d
13 Jun 23
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC
8:31am
8-K
EX-99.1
24errj6yume1a
8 Jun 23
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
8:15am
8-K
EX-99.2
5lx3q
19 May 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
jd5vut3tzth1cunalm
19 May 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
w5qk0yg1zji jf
11 May 23
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:31am